Literature DB >> 26434556

Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia.

Akihito Fujimi1, Soushi Ibata1, Yuji Kanisawa1, Takanori Shibata2, Hiroki Sakamoto2, Shota Yamada2, Toshinori Okuda2, Sho Takahashi2, Shinya Minami2, Akari Hashimoto3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26434556     DOI： 10.1111/1346-8138.13150

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  3 in total

Review 1.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

2.  Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.

Authors:  Kirsten C Webb; Magdalena Harasimowicz; Monica Janeczek; Jodi Speiser; James Swan; Rebecca Tung
Journal:  Case Rep Dermatol Med       Date:  2017-03-23

3.  Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature.

Authors:  Bader Alharbi; Samer Alamri; Ahmed Mahdi; Siham Marghalani
Journal:  Case Rep Dermatol Med       Date:  2018-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.